Professor Liu Yong gave a brief explanation on the current status of tumor bioimmunotherapy at home and abroad, foreign development, and domestic application. He also discussed the application and research of ACTL technology with Secretary Chen of the institute and the researchers of the institute. They had a lively discussion and proposed to find an entry point for cooperation. For tumor biotherapy, the leaders of the hospital conformed to clinical needs and the general trend of international development, gave a high evaluation of our company's targeted anti-tumor immune technology, and conducted extensive communication on how to cooperate in the future. All reached a consensus.